

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	Application Number	10/798,652
	Filing Date	March 11, 2004
	First Named Inventor	Yongjun Guo
	Art Unit	1634
	Examiner Name	Katherine D. Salmon
Total Number of Pages in This Submission		Attorney Docket Number 3882-P03136US01

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	15 Cited References
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<b>Remarks</b> In the event the that a fee is required in connection with this submission and not enclosed, the Commissioner is authorized to charge such fee to the account of the undersigned attorneys, Account No. 04-1406. A duplicate copy of this sheet is enclosed.	

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	DANN, DORFMAN, HERRELL AND SKILLMAN - Cusotmer No. 000110		
Signature			
Printed name	Tong Li		
Date	March 22, 2006	Reg. No.	47,748

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name	Jane C. Bogan	Date	March 22, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of ) Examiner: Salmon, K.D.  
Yongjun Guo ) Art Unit: 1634  
Serial No.: 10/798,652 )  
Filed: March 11, 2004 )  
For: "SINGLE NUCLEOTIDE )  
POLYMORPHISM IN THE FGF-3 )  
GENE AND METHODS OF USE )  
THEREOF" )

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with the provisions of 37 C.F.R. §1.56, applicants hereby submit the attached two (2) sheets of PTO form PTO/SB/08B, listing references which the Patent Examiner is requested to consider and make of record in the above-identified application. Copies of the listed references are enclosed herewith. This submission is believed to be in full compliance with the requirements of 37 C.F.R. §1.98.

In the opinion of the undersigned, the foregoing references are the most pertinent of which the undersigned is aware. However, no representation is made or intended that more pertinent references do not exist.


This submission is not an admission that the reference listed on the attached PTO form PTO/SB/08B constitute prior art against the claims of this application.

The Examiner is respectfully requested to confirm receipt and consideration of the cited references by initialing the returning a copy of the attached PTO form PTO/SB/08B in accordance with MPEP §609.

Early and favorable consideration leading to prompt issuance of this application is earnestly solicited.

This submission is made more than three (3) months after the filing date but before receipt of the first office action on merits. Therefore, no fee is required. In the event any fee is due in connection with the consideration of this request, the Commissioner is authorized to charge any such fee to the account of the undersigned attorneys, Deposit Account No. 04-1406.

Respectfully submitted,  
DANN, DORFMAN, HERRELL AND SKILLMAN  
A Professional Corporation

By   
Tong Li  
PTO Registration No. 47,748

Telephone: (215) 563-4100  
Facsimile: (215) 563-4044



PTO/SB/08B (07-05)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/798,652
		Filing Date	March 11, 2004
		First Named Inventor	Yongjun Guo
		Art Unit	1634
		Examiner Name	Salmon, K.D.
Sheet 1	of 2	Attorney Docket Number	3882-PO3136US01

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Fan, C. et al., "Frequent c-myc and int-2 Overrepresentations in Nasopharyngeal carcinoma", Human Pathology 31(2):169-178 (2000)	
	C2	Ikeda Y. et al., "Meanings of c-erbB and int-2 Amplification in Superficial Esophageal Squamous Cell Carcinomas", Ann Thorac Surg 62:835-838 (1996)	
	C3	Schraml P. et al., "Combined Array Comparative Genomic Hybridization and Tissue Microarray Analysis Suggest PAK1 at 11q13.5-q14 as a ....", Am J Pathol 163(3):985-992 (2003)	
	C4	Hui R. et al., "EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in ...", Oncogene 15:1617-1623 (1997)	
	C5	Maharivea B.M. et al., "High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer", J Pathol 201:603-608 (2003)	
	C6	Galdemard C. et al., "Regulation of FGF-3 Gene Expression in Tumorigenic and Non-tumorigenic Clones of a Human Colon Carcinoma cell Line", J Bio Chem 275(23):17364-17373 (2000)	
	C7	Hajitou A. et al., "Progression in MCF-7 breast cancer cell tumorigenicity: compared effect of FGF-3 and FGF-4", Breast Cancer Research and Treatment 60:15-28 (2000)	
	C8	Fioravanti L. et al., "int-2 Oncogene Amplification and Prognosis in Node-negative Breast Carcinoma", Int J Cancer 74:620-624 (1997)	
	C9	Tseloni-Balafouta S. et al., "A comparative study of the int-2 gene product in primary and secondary parathyroid lesions", European Journal of Endocrinology 146:57-60 (2002)	
	C10	Medl M. et al., "DNA Amplification of HER-2/neu and INT-2 Oncogenes in Epithelial Ovarian Cancer", Gynecologic Oncology 59:321-326 (1995)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/798,652
		Filing Date	March 11, 2004
		First Named Inventor	Yongjun Guo
		Art Unit	1634
		Examiner Name	Salmon, K.D.
		Attorney Docket Number	3882-PO3136US01
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C11	Dobianer K. et al., "HER-2 Amplification but Not Butyrylcholinesterase Mutability Reflects Aggressiveness of European-Originated ...", Gynecologic Oncology 56:200-206 (1995)	
	C22	Ropiquet F., "Increased Expression of Fibroblast Growth Factor 6 in Human Prostatic Intraepithelial Neoplasia and Prostate Cancer", Cancer Research 60:4245-4250 (2000)	
	C13	Roh H.J. et al., "Visualization fo the Timing of Gene Amplification during Multistep Head and Neck Tumorigenesis", Cancer Research 60:6496-6502 (2000)	
	C14	Arai H. et al., "Dectection of amplified oncogenes by genome DNA microarrays in human primary esophageal squamous cell ..." Cancer Genetics and Cytogenetcs 146:16-21 (2003)	
	C15	Dickson C. et al., "Tumorigenesis by Mouse Tumor Virus: Proviral Activation of a Cellular Gene in the Common Integration Region int-2", Cell 37:529-536 (1984)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.